ENTYVIO for UC
Results for Patients with Ulcerative Colitis
ENTYVIO helps control gastrointestinal (GI) inflammation that occurs in adults with moderately to severely active ulcerative colitis when certain other medicines have not worked well enough or cannot be tolerated.
In clinical studies, ENTYVIO was shown to help many patients achieve results.
Early Results
Early Results
- At Week 6, 47% of patients on ENTYVIO achieved clinical response compared to 26% on placebo.
Long-Term Remission
Long-Term Remission
- At 1 year, 42% of patients achieved remission compared to 16% of patients on placebo.
Some patients with ulcerative colitis experienced improvement in how their intestinal lining looked to their doctor.
- As early as Week 6, 41% of patients experienced improvement in how their intestinal lining looked to their doctor*
-
At 1 year, 52% of patients experienced improvement in how their intestinal lining looked to their doctor†
*Compared to 25% of patients on placebo at Week 6.
†Compared to 20% of patients on placebo at 1 year.
Individual results may vary.
In a separate head-to-head study, at one year, ENTYVIO helped significantly more moderate to severe ulcerative colitis patients than HUMIRA®‡ (adalimumab) to achieve remission.
-
At 1 year, 31.3% of ENTYVIO patients achieved remission compared to 22.5% of HUMIRA patients in a clinical study.
‡HUMIRA® AbbVie, Inc. North Chicago, IL.
For more information related to adalimumab, please see www.abbvie.com.
Individual results may vary.
